---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115344"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:17:23.812640+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q3 revenue flat YoY at $56.7M; services up 9%, product down 14%

## Summary
- Net loss attributable to common stockholders: $1.2M ($0.02/share) vs $15.3M loss ($0.31) YoY.
- Life Sciences Services revenue up 9% to $39.3M; gross margin improved to 46%.
- Life Sciences Products revenue down 14% to $17.4M; total gross margin 44.8%.
- Full-year 2024 revenue guidance reaffirmed at $225-235M; management targets positive adjusted EBITDA in 2025.
- Repurchased $175M principal of 2026 convertible notes for $154.5M; cash and short-term investments $272.7M.

## SEC filing metadata
- accession: 0001104659-24-115344
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465924115344/0001104659-24-115344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465924115344/tm2427809d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115344
- JSON: https://secwatch.observer/filing/0001104659-24-115344.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.